Literature DB >> 23440574

Pathophysiology and management of thrombosis in cancer: 150 years of progress.

Gerald A Soff1.   

Abstract

The association of thrombosis with cancer has been recognized since the middle of the nineteenth century. It remains a common and serious complication of the cancer itself, as well as chemotherapy. Thrombosis is the second leading cause of death in cancer patients, second only to the cancer itself. For many years the treatment options for managing thrombosis in cancer had been static, but the past decade has seen significant evolution in the management, with the clear superiority of low molecular weight heparin over warfarin for secondary prevention of thrombosis. This article will review the understanding and management of thrombosis in cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440574     DOI: 10.1007/s11239-013-0897-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  50 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

Review 2.  A new generation of oral direct anticoagulants.

Authors:  Gerald A Soff
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

3.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

Review 4.  Molecular basis for the relationship between thrombosis and cancer.

Authors:  F R Rickles; A Falanga
Journal:  Thromb Res       Date:  2001-06-15       Impact factor: 3.944

Review 5.  Thrombosis in cancer patients.

Authors:  H F Hillen
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

6.  Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients.

Authors:  C Font; B Farrús; L Vidal; T M Caralt; L Visa; B Mellado; D Tàssies; J Monteagudo; J C Reverter; P Gascon
Journal:  Ann Oncol       Date:  2011-02-16       Impact factor: 32.976

7.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

Review 8.  Venous thromboembolism: disease burden, outcomes and risk factors.

Authors:  J A Heit
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 9.  Genetic link between cancer and thrombosis.

Authors:  Carla Boccaccio; Paolo M Comoglio
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

10.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

View more
  1 in total

Review 1.  Cancer-associated thrombosis: an overview.

Authors:  Ghaleb Elyamany; Ali Mattar Alzahrani; Eman Bukhary
Journal:  Clin Med Insights Oncol       Date:  2014-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.